# Retatrutide FAQ: Questions from the Research Community, Answered > Frequently asked questions about retatrutide — half-life, mechanism, availability, FDA status, side effects, and comparisons — answered from the published trial record. Direct answers drawn from published Phase 1b and Phase 2 data. No dosing guidance, no medical advice. ## What is the half-life of retatrutide? Approximately 6 days. Established in the Phase 1b first-in-human trial of LY3437943 in people with type 2 diabetes [4]. That half-life supports once-weekly subcutaneous dosing by keeping plasma concentrations above trough between injections. For the full pharmacokinetic context, see [retatrutide half life](/half-life). ## What is retatrutide's half-life and how long does it stay in the body? Phase 1b data established a half-life of approximately 6 days [4]. This means the plasma concentration halves every ~6 days. After a single dose, clinically meaningful levels are present for roughly 3–4 weeks before dropping to negligible concentrations. For a compound administered weekly, this produces a relatively stable exposure profile at steady state — concentration rises to a plateau after approximately 4–5 weekly doses. ## What does retatrutide do? Retatrutide activates three hormone receptors simultaneously: the GLP-1 receptor (appetite suppression and glucose-dependent insulin release), the GIP receptor (insulinotropic and adipose effects), and the glucagon receptor (increased energy expenditure and hepatic lipid metabolism). In Phase 2 obesity trials the combination produced up to -24.2% body-weight change at 48 weeks [1]. A 2025 review characterized the efficacy profile as a step-change versus prior incretin therapies [6]. ## How does retatrutide work? Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone. It is acylated (attached to a fatty-acid chain) for albumin binding, which slows clearance and extends the half-life to ~6 days [4]. At the receptor level, it engages GLP-1R, GIPR, and GCGR simultaneously — cryo-EM structural studies have resolved these binding interactions at near-atomic resolution [3]. The GLP-1 and GIP arms suppress appetite and improve glucose handling; the glucagon arm adds energy expenditure. See [how does retatrutide work](/how-it-works) for a full mechanism account. ## How to reconstitute retatrutide? No standardized reconstitution protocol exists for retatrutide because no approved pharmaceutical product of retatrutide has been marketed. Clinical trial formulations were pharmaceutical-grade GMP products administered by clinicians — not reconstituted from lyophilized powder by participants. Gray-market vials sold through research channels have no verified identity, concentration, or sterility. This digest does not provide reconstitution guidance. ## Is retatrutide FDA approved? No. Retatrutide is not FDA-approved and not approved by any regulator as of mid-2026. It is an investigational new drug undergoing Phase 3 trials (the TRIUMPH program). It cannot legally be prescribed, dispensed, or sold as a pharmaceutical product. The TRIUMPH-2, TRIUMPH-3, and cardiovascular outcomes trials are ongoing; no approval date has been announced. ## When will retatrutide be available? No approval timeline has been announced. The Phase 3 TRIUMPH trials are ongoing. For a new drug to become available, Phase 3 must complete, Eli Lilly must submit a New Drug Application (NDA), and the FDA must review and approve it — a process that typically takes 1–2 years from submission. Retatrutide availability as a prescription product remains conditional on those regulatory steps. ## Retatrutide availability — is there any legal way to get it? The only legal way to receive retatrutide is through enrollment in one of its clinical trials (the TRIUMPH program or related studies). Clinical trial locators at ClinicalTrials.gov list open studies. Outside of trials, no legal prescription or dispensing of retatrutide is possible because the drug has no approved indication. Gray-market research-labeled products cannot be verified as authentic and are unregulated. ## How to take retatrutide? In all published clinical trials, retatrutide was administered as a subcutaneous injection (under the skin) once weekly. This is the route studied; no oral or other formulation has been published. Because retatrutide is not approved, there is no official prescribing information or administration guidance. This digest documents how it was administered in trials but does not instruct on human self-administration. ## How long does retatrutide take to work? Phase 2 trial data show measurable weight-loss effects from the first weeks of treatment, with progressive weight loss through 48 weeks — at which point the trajectory had not yet plateaued at the highest dose [1]. The ~6-day half-life means steady-state plasma concentrations are reached after approximately 4–5 weeks of once-weekly dosing. A 2025 review characterized the early and sustained efficacy as distinctive relative to prior incretin therapies [6]. ## Is retatrutide better than tirzepatide? No head-to-head data are yet published. A direct-comparison Phase 3 trial (NCT06662383) is ongoing [11]. Comparing Phase 2 retatrutide data (48 weeks, -24.2% body weight at 12 mg) against separate trials of tirzepatide is methodologically limited — different populations, durations, baseline characteristics, and comparator arms. The active-comparator trial was specifically designed because separate Phase 2 datasets cannot answer the comparative question. ## How much retatrutide per week? In the Phase 2 obesity trial, doses of 1, 4, 8, and 12 mg once weekly were studied [1]. The highest dose studied (12 mg) produced the largest weight reduction (-24.2% at 48 weeks). These are study-design facts documenting what was administered in a controlled trial — not dosing guidance and not applicable to any non-trial context. ## How to mix retatrutide with bacteriostatic water? This digest does not provide reconstitution guidance for gray-market injectable compounds. No approved pharmaceutical product of retatrutide exists that would carry a reconstitution standard. Clinical trial formulations were not mixed by participants. Gray-market vials lack verified identity, concentration, and sterility — making any reconstitution guidance from an editorial source both unfounded and potentially unsafe to follow. ## How to switch from tirzepatide to retatrutide? This question presupposes that retatrutide is available as an approved or prescribable drug. It is not. Retatrutide is investigational and cannot be legally prescribed or dispensed. No clinical protocol for transitioning from one approved agent to retatrutide has been published. The active-comparator trial (NCT06662383) compares the two compounds head-to-head in a controlled setting, not as a sequential switch [11]. ## Is retatrutide a GLP-3? No. There is no GLP-3 receptor. Retatrutide is a triple agonist at three existing receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. The "GLP-3" label is a misnomer that circulates online — it appears to arise from casual use of "triple" to mean "GLP-3" (as in the third GLP drug by colloquial numbering), not from any receptor nomenclature. The correct description is: triple GIP/GLP-1/glucagon receptor agonist [3][6]. ## Is retatrutide legal? Retatrutide is not illegal to possess in most jurisdictions, but it is not approved for sale, dispensing, or prescription use. Gray-market possession of research-labeled retatrutide occupies a regulatory gray zone. The FDA has issued warning letters to vendors for distributing it in violation of the FD&C Act. Athletes should note that while GIP/GLP-1/glucagon agonists are not specifically named on the current WADA Prohibited List, the status of investigational agents can change and should be checked against the current code. ## How often do you take retatrutide? All published trials administered retatrutide subcutaneously once weekly [1][2][4]. The dosing frequency is directly supported by the pharmacokinetics: a half-life of approximately 6 days means trough concentrations between weekly doses remain pharmacologically relevant, producing a stable exposure profile at steady state. No approved prescribing information exists because the drug is not approved. ## How to store retatrutide? No consumer or research-product storage standard exists for retatrutide. Clinical trial formulations are pharmaceutical-grade products held to pharmaceutical cold-chain conditions. Gray-market preparations have no verified stability data. The Phase 2 trials noted retatrutide was "studied only as a clinical-trial investigational product administered by once-weekly subcutaneous injection; no approved formulation, storage, or reconstitution standard exists for any non-trial preparation." ## Is retatrutide the same as Ozempic? No. Retatrutide and semaglutide (the generic name of the active ingredient in Ozempic) are different compounds. Semaglutide is a GLP-1 receptor agonist only — it activates one receptor. Retatrutide is a triple agonist at GIP, GLP-1, and glucagon receptors — three receptors. Additionally, semaglutide is FDA-approved and commercially available; retatrutide is investigational and not approved. Brand names are not used in this digest; the relevant generic names are semaglutide and retatrutide. ## Is retatrutide better than semaglutide? No direct head-to-head clinical data comparing retatrutide and semaglutide have been published as of mid-2026. Phase 2 retatrutide data (-24.2% body weight at 12 mg/48 weeks) have been compared descriptively to Phase 3 semaglutide data in review articles, but these are separate trials with different populations and durations. The head-to-head Phase 3 trial currently underway (NCT06662383) compares retatrutide to tirzepatide — not semaglutide. ## What is retatrutide used for? In clinical trials, retatrutide has been studied for obesity (as a weight-management agent), type 2 diabetes (blood glucose control and weight reduction), and MASLD (metabolic dysfunction-associated steatotic liver disease, or fatty liver linked to metabolic factors). It is not approved for any of these indications. A 2025 review also notes the class is being evaluated for cardiovascular and kidney outcomes [6]. ## What receptors does retatrutide target? Retatrutide simultaneously targets three receptors: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). Cryo-EM structural studies resolved retatrutide's binding at each receptor at near-atomic resolution [3]. Relative potency compared to the endogenous hormones: approximately 8.9x more potent than native GIP at GIPR, 0.4x as potent as native GLP-1 at GLP-1R, and 0.3x as potent as native glucagon at GCGR. The GIPR super-potency and blunted GCGR potency are deliberate design features — they allow glucagon-driven energy expenditure while limiting the hyperglycemic effect of full glucagon-receptor activation. ## Retatrutide cost — what is known? Retatrutide has no approved price because it is not a marketed product. Eli Lilly has not announced a list price. Analysts and health-economics commentators have speculated that, if approved, pricing would likely be similar to or above current GLP-1 class agents ($1,000–$1,500/month list before rebates), but these are informed estimates, not declared prices. Gray-market research-labeled material is sold online at varying prices, but those products have no verified identity or regulatory status. --- A methodical reading of the published retatrutide trial record — Phase 1b pharmacokinetics through Phase 3 program, every figure walked to its source and the investigational status held in plain view; not a clinic, not a telehealth service, and nothing here dispensed or prescribed.